Pancreatic Cancer Research

ResearcherUniversity of AntwerpActive in the last 2 years

Marc Peeters

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4969-2303; OpenAlex author ID A5024390084, A5128691810. Sources: ClinicalTrials.gov.

Their work

Papers
17 (first author 1, last author 2)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
0
Collaborators
61
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper, 2 trials · 2022: 3 papers · 2023: 4 papers · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 17

  1. Protein-level profiling of TIGIT axis components in human PDAC reveals immune-suppressive expression patterns. Co-author DOI 10.1007/s00262-026-04343-w↗
  2. Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by… Co-author DOI 10.1186/s13046-024-03012-z↗
  3. Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic… Co-author DOI 10.1002/cam4.6621↗
  4. Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer. Co-author DOI 10.1038/s41698-023-00480-y↗
  5. Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy. Co-author DOI 10.1080/14737140.2023.2270161↗
  6. A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcin… Last author DOI 10.1177/17588359231181500↗
  7. Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer. Co-author DOI 10.1016/j.esmoop.2022.100386↗
  8. Targeting hedgehog signaling in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pharmthera.2022.108107↗
  9. Development, Testing, and Implementation of the Belgian Patient Reported Experience Measure for Pancreatic Cancer Care (PREPARE) Project: Protocol for a Multi-… First author DOI 10.2196/29004↗
  10. Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Co-author DOI 10.3390/cancers13050987↗
  11. Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment. Co-author DOI 10.1002/cti2.1165↗
  12. Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells. Co-author DOI 10.3390/cancers11101597↗
  13. Natural killer cells and their therapeutic role in pancreatic cancer: A systematic review. Co-author DOI 10.1016/j.pharmthera.2018.04.003↗
  14. Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Co-author DOI 10.1007/s11523-016-0469-y↗
  15. Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. Co-author DOI 10.18632/oncotarget.18185↗
  16. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Co-author DOI 10.1093/annonc/mdr351↗
  17. Noninvasive monitoring of therapy-induced microvascular changes in a pancreatic cancer model using dynamic contrast-enhanced magnetic resonance imaging with P8… Last author DOI 10.1667/rr2068.1↗

Trials 2

  1. Safety Study of Whole Body Hyperthermia for Advanced Cancer Principal investigator NCT04467593↗
  2. Retrospective Study on the Efficacy and Tolerability of Liposomal Irinotecan Principal investigator NCT05095064↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Geert Roeyen · 9 shared papers, 2017–2026 · strength 1.25
  2. Evelien Smits · 8 shared papers, 2017–2024 · strength 0.92
  3. Jonas R.M. Van Audenaerde · 7 shared papers, 2017–2026 · strength 0.83
  4. Hans Prenen · 5 shared papers, 2021–2026 · strength 0.83
  5. Delphine Quatannens · 4 shared papers, 2020–2026 · strength 0.60
  6. Christophe Deben · 4 shared papers, 2019–2024 · strength 0.52
  7. Timon Vandamme · 3 shared papers, 2021–2023 · strength 0.47
  8. Jean‐Luc Van Laethem · 4 shared papers, 2012–2023 · strength 0.40
  9. Maxim Le Compte · 2 shared papers, 2023–2024 · strength 0.33
  10. Andreas Domen · 2 shared papers, 2021–2023 · strength 0.26
  11. Jinthe Van Loenhout · 3 shared papers, 2017–2020 · strength 0.23
  12. Timothy Jay Price · 1 shared paper, 2023 · strength 0.20
  13. Barbara Geerinckx · 1 shared paper, 2023 · strength 0.20
  14. Melissa Horlait · 1 shared paper, 2022 · strength 0.20
  15. Katrien Moens · 1 shared paper, 2022 · strength 0.20
  16. Talia Golan · 1 shared paper, 2023 · strength 0.17
  17. Jean‐Frédéric Blanc · 1 shared paper, 2023 · strength 0.17
  18. Lise Verbruggen · 1 shared paper, 2023 · strength 0.17
  19. Joan Maurel Santasusana · 1 shared paper, 2023 · strength 0.17
  20. Chung‐Pin Li · 1 shared paper, 2023 · strength 0.17
  21. Vincent J. Picozzi · 1 shared paper, 2023 · strength 0.17
  22. Elena Gabriela Chiorean · 1 shared paper, 2023 · strength 0.17
  23. Howard S. Höchster · 1 shared paper, 2023 · strength 0.17
  24. Karen Paula Geboes · 1 shared paper, 2022 · strength 0.16
  25. Frederik Christiaan Berrevoet · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.